On December 30, Gelonghui reported that CANSINOBIO (06185.HK) announced that its ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) ("MCV4", Commodity name: Manhai Xin) has obtained the registration certificate granted by the Indonesian Food and Drug Administration.
MCV4 is suitable for infants from 3 months to 3 years old (up to 47 months). Vaccination with MCV4 can stimulate the body to produce immunity against ACYW135 group Neisseria meningitidis, which is used to prevent epidemic meningitis caused by ACYW135 group Neisseria meningitidis. Clinical trials conducted in China have shown good safety and immunogenicity. MCV4 is currently being evaluated in Indonesia in clinical trials for safety and immunogenicity after vaccination in the 18 to 55 age group, with the aim of expanding the applicable population. The registration certificate obtained in Indonesia for MCV4 is an important achievement of the product's Global Strategy, which is beneficial for the company to enhance its overseas brand awareness and international influence.
